Skin carcinoma

Summary

Skin carcinoma (MONDO:0002656) is a cancer (an umbrella term covering 13 Mondo subtypes) and 94 clinical trials. Top therapeutic interventions include dabrafenib, niacinamide, and afatinib. A subtype of skin cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 13 Mondo subtypes
• Clinical trials: 94

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	skin carcinoma
Mondo ID	MONDO:0002656
EFO	EFO:0009259
DOID	DOID:3451
NCIT	C4914
UMLS	C0699893
MedGen	195945
Anatomy (UBERON)	UBERON:0000014
Is cancer (heuristic)	yes

Also known as: carcinoma of skin · carcinoma of the skin · carcinoma of zone of skin · non-melanoma cancer of skin · non-melanoma cancer of the skin · non-melanoma skin cancer · nonmelanoma skin cancer · skin cancer, non-melanoma · skin carcinoma · zone of skin carcinoma

Disease family

This is a subtype of skin cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › skin cancer › skin carcinoma

Related subtypes (12): labium majus cancer, labia minora cancer, prepuce cancer, sweat gland cancer, cutaneous ganglioneuroma, malignant dermis tumor, skin meningioma, cutaneous melanoma, primary cutaneous lymphoma, CD4+/CD56+ hematodermic neoplasm, eyelid cancer, sebaceous gland cancer

Subtypes (13): labia minora carcinoma, labia majora carcinoma, skin squamous cell carcinoma, cutaneous Paget disease, anal margin carcinoma, cutaneous mucoepidermoid carcinoma, eyelid carcinoma, Borst-Jadassohn intraepidermal carcinoma, skin carcinoma in situ, skin basal cell carcinoma, vulvar seborrheic keratosis, skin appendage carcinoma, cutaneous neuroendocrine carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Nivolumab	Phase 3 (in late-stage trials)
Sirolimus	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Capecitabine, Fluorouracil, PEGINTERFERON ALFA-2B, Pembrolizumab, Tazarotene, Vilobelimab.

Clinical trials & evidence

Clinical trials

Clinical trials: 94.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	58
PHASE2	15
PHASE1	9
PHASE1/PHASE2	6
PHASE3	2
EARLY_PHASE1	2
PHASE4	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01053819	PHASE4	COMPLETED	Can We Miss Pigmented Lesions in Psoriasis Patients?
NCT05955924	PHASE3	RECRUITING	Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
NCT07440290	PHASE2/PHASE3	NOT_YET_RECRUITING	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
NCT03131713	PHASE3	COMPLETED	Preoperative Acetaminophen and Carbohydrate Loading
NCT02465060	PHASE2	ACTIVE_NOT_RECRUITING	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT03767348	PHASE2	ACTIVE_NOT_RECRUITING	Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT04844528	PHASE2	RECRUITING	Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
NCT05878288	PHASE2	ACTIVE_NOT_RECRUITING	Deep sequencIng in Cutaneous Squamous CEll caRciNomas
NCT06409195	PHASE2	RECRUITING	A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers
NCT07410676	PHASE1/PHASE2	RECRUITING	EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
NCT00783965	PHASE2	COMPLETED	Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
NCT01359735	PHASE2	COMPLETED	Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients
NCT02080962	PHASE2	TERMINATED	Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer
NCT02423863	PHASE2	COMPLETED	In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
NCT02636569	PHASE2	COMPLETED	Topical Chemoprevention of Skin Cancer Biomarkers
NCT02964559	PHASE2	COMPLETED	Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
NCT03110159	PHASE1/PHASE2	COMPLETED	DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients
NCT03327064	PHASE1/PHASE2	WITHDRAWN	A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer
NCT03769285	PHASE2	UNKNOWN	Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial
NCT04091022	PHASE2	COMPLETED	Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer
NCT04410874	PHASE1/PHASE2	TERMINATED	Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer
NCT04470726	PHASE1/PHASE2	COMPLETED	Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype
NCT05315128	PHASE2	COMPLETED	Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers
NCT05429866	PHASE2	UNKNOWN	Immunological Variables Associated to ICI Toxicity in Cancer Patients
NCT05602792	PHASE1/PHASE2	UNKNOWN	A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
NCT07118176	PHASE1	RECRUITING	Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
NCT00954226	PHASE1	COMPLETED	Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
NCT01242618	PHASE1	COMPLETED	Tissue Engineered Nasal Cartilage for Reconstruction of the Alar Lobule
NCT01727076	PHASE1	COMPLETED	Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
NCT02318771	PHASE1	COMPLETED	Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
NCT03458117	PHASE1	COMPLETED	T-VEC in Non-melanoma Skin Cancer
NCT04160065	PHASE1	COMPLETED	Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers
NCT04348916	PHASE1	TERMINATED	Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
NCT04456140	PHASE1	COMPLETED	Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
NCT03543969	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
NCT05932511	EARLY_PHASE1	UNKNOWN	Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer
NCT03906253	Not specified	RECRUITING	Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia
NCT04358276	Not specified	ACTIVE_NOT_RECRUITING	Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study
NCT04475640	Not specified	RECRUITING	Cancer Genetic Testing in Ethnic Populations
NCT05108090	Not specified	RECRUITING	Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DABRAFENIB	4	3
NIACINAMIDE	4	3
AFATINIB	4	2
AMINOLEVULINIC ACID HYDROCHLORIDE	4	2
COPANLISIB	4	2
LAROTRECTINIB	4	2
TRAMETINIB	4	2
BACITRACIN	4	1
BINIMETINIB	4	1
CAPIVASERTIB	4	1
CEMIPLIMAB	4	1
CRIZOTINIB	4	1
DICLOFENAC SODIUM	4	1
EFLORNITHINE HYDROCHLORIDE	4	1
ENCORAFENIB	4	1
ERDAFITINIB	4	1
ETANERCEPT	4	1
OSIMERTINIB	4	1
PALBOCICLIB	4	1
RELATLIMAB	4	1
SUNITINIB MALATE	4	1
TAZAROTENE	4	1
TRASTUZUMAB EMTANSINE	4	1
VISMODEGIB	4	1
DEFACTINIB	3	3
LAVENDER OIL	3	2
IPATASERTIB	3	1
SELENIUM	3	1
TASELISIB	3	1
VUSOLIMOGENE ODERPAREPVEC	3	1